Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma

Daniel Guy, Brad S. Kahl

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Mantle cell lymphoma is an incurable B-cell malignancy. Treatment of young fit patients is particularly challenging, because careful consideration should be made when building a long-term treatment strategy that would provide longer remissions and increase patients’ quality of life. Most young fit patients achieve long remissions with a combination of immunochemotherapy containing rituximab and high-dose cytarabine, followed by high-dose chemotherapy and autologous stem-cell transplantation. The addition of maintenance therapy with rituximab following autologous stem-cell transplantation prolongs the time to relapse and increases overall survival. Despite an intensive approach, late relapses are common and are usually treated with novel agents.

Original languageEnglish
Pages (from-to)861-870
Number of pages10
JournalHematology/Oncology Clinics of North America
Issue number5
StatePublished - Oct 2020


  • Autologous stem cell transplantation
  • Clinical trials
  • Mantle cell lymphoma
  • Novel therapeutics


Dive into the research topics of 'Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma'. Together they form a unique fingerprint.

Cite this